Related studies have also shown that combined cytotoxic chemotherapy and EGFR-TKI treatment can help improve the remission rate and PFS rate of SCLC transformation (30–32), so in addition to the treatment of SCLC, we should also pay attention to the treatment of the primary lung cancer type (6). This evidence concerns the gene EGFR and small cell lung carcinoma.